Over 30 types of pediatric brain and spinal cord tumor clinical and molecular data, biospecimens, and cell-lines are available at no cost to academic researchers. Our open science model has shortened research time by up
to 20 years.
By working together to collect and share resources, we can save more children.
Brain and CNS tumors are the most common cause of disease related death in children aged 0–19 years in the U.S. and across the globe, with approximately 412,000 children and young adults living with a brain tumor each year.
Pediatric meningiomas are extremely rare tumors and are often of an aggressive form unresponsive to available treatments. Specimens from the Pediatric Brain Tumor Atlas will allow researchers to study this rare tumor in an effort to develop targeted therapies.
Medulloblastoma, HGG, LGG, Ependymoma, Meningioma, Schwannoma
Newly developed technology is advancing the ability of researchers to gain important insight from small clinical specimens.
Changes to DNA that can give rise to cancers often create fusion proteins, proteins that may be useful as therapeutic targets. Using data from the Pediatric Brain Tumor Atlas, researchers will analyze for the presence of such proteins in an effort to advance treatment options for pediatric brain cancers.
The Gabriella Miller Kids First Data Resource Portal provides access to more than 8,000 samples of childhood cancer and structural birth defects genomic data. The Kids First Data Resource Portal stores the CBTN's Pediatric Brain Tumor Atlas data and allows cross-analysis of different disease types to uncover the potential links between genetic diseases occurring in children. Kids First DRC Git Hub
The PedcBioPortal is an open-access resource for childhood cancer genomics which enables users to visualize, analyze and also download large-scale cancer genomics data sets. These data allow researchers to understand the molecular mechanisms of cancer and design therapies based on a patient's unique profile.PedcBioPortal is a variation upon the original cBioPortal (developed at Memorial Sloan Kettering) which allows investigators and researchers to rapidly explore data stored in the adult-focused TCGA database. Although this adult data is accessible through PedcBioPortal, the platform focuses on analysis of high-quality childhood cancer datasets. This platform works uniquely within the CBTN applications ecosystem to empower research and the translation of genomics data into biological insights and improved clinical therapies.
Cavatica is a cloud-based portal environment developed to securely store, share and analyze large volumes of pediatric brain tumor genomic data to accelerate collaboration in research. Named for the popular children’s story Charlotte’s Web, Cavatica allows researchers and investigators to access and share a network of data, pipelines, algorithms, visualizations, and hypotheses’ about specific types of tumors. Cavatica includes data from a number of sources including the Children’s Brain Tumor Tissue Consortium (CBTN), Pacific Neuro-oncology Consortium (PNOC), Stand Up to Cancer, TARGET and TCGA.Cavatica is improving collaboration between data scientists, statisticians, data engineers, programmers, application developers, bioinformaticians and scientists. Following its launch in October 2016, Cavatica has grown to become the largest clinically annotated pediatric cancer database on earth.
Childhood craniopharyngiomas are rare tumors usually found near the pituitary gland (a pea-sized organ at the bottom of the brain that controls other glands) and the hypothalamus (a small cone-shaped organ connected to the pituitary gland by nerves).Craniopharyngiomas are usually part solid mass and
Medulloblastomas comprises the vast majority of pediatric embryonal tumors and by definition arise in the posterior fossa, where they constitute approximately 40% of all posterior fossa tumors. Other forms of embryonal tumors each make up 2% or less of all childhood brain tumors.The clinical feature
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test